Literature DB >> 1311239

A specific, high affinity, saturable binding site for the 16-kilodalton fragment of prolactin on capillary endothelial cells.

C Clapp1, R I Weiner.   

Abstract

A 16-kilodalton N-terminal fragment of PRL (16K PRL) is formed by enzymatic cleavage of intact 23-kilodalton PRL (23K PRL) in the pituitary gland and in target tissues for PRL. 16K PRL inhibits the growth of capillary endothelial cells, while intact PRL was inactive suggesting that 16K PRL acted via a receptor other than the PRL receptor. To analyze whether this inhibitory effect could be mediated through an specific 16K PRL receptor, we characterized the binding of 16K PRL to membrane preparations of bovine brain capillary endothelial (BBE) cells. 16K PRL was generated by the proteolysis of rat 23K PRL with a particulate fraction from rat mammary gland homogenates and purified by gel filtration. The specific binding of [125I]16K PRL to BBE cell membranes was high affinity (Kd = 9.9 nM), saturable (Bmax = 4.8 pmol/mg protein), and reversible. In competition studies for [125I]16K PRL binding, 16K PRL was most potent, while little displacement was observed with high concentrations of 23K PRLs, growth hormones, and basic fibroblast growth factor. Blockade of reformation of disulfide bonds by carbamidomethylation of 16K PRL, a procedure which increases the biological activity of the molecule, increased its binding affinity (Kd = 0.9 nM). Cross-linking experiments identified a 52,000 and a 32,000 mol wt protein as the major 16K PRL binding species. These data demonstrate the presence of specific, high affinity, saturable binding sites for 16K PRL on BBE cell membranes and support biological findings that 16K PRL inhibits capillary endothelial cell proliferation, through a novel, high affinity receptor.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1311239     DOI: 10.1210/endo.130.3.1311239

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  36 in total

Review 1.  16-kDa prolactin and bromocriptine in postpartum cardiomyopathy.

Authors:  Denise Hilfiker-Kleiner; Ingrid Struman; Melanie Hoch; Edith Podewski; Karen Sliwa
Journal:  Curr Heart Fail Rep       Date:  2012-09

2.  Prolactin/growth hormone-derived antiangiogenic peptides highlight a potential role of tilted peptides in angiogenesis.

Authors:  Ngoc-Quynh-Nhu Nguyen; Sebastien P Tabruyn; Laurence Lins; Michelle Lion; Anne M Cornet; Florence Lair; Francoise Rentier-Delrue; Robert Brasseur; Joseph A Martial; Ingrid Struman
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-14       Impact factor: 11.205

3.  Opposing actions of intact and N-terminal fragments of the human prolactin/growth hormone family members on angiogenesis: an efficient mechanism for the regulation of angiogenesis.

Authors:  I Struman; F Bentzien; H Lee; V Mainfroid; G D'Angelo; V Goffin; R I Weiner; J A Martial
Journal:  Proc Natl Acad Sci U S A       Date:  1999-02-16       Impact factor: 11.205

4.  Introduction: hormones, blood cells and immunity, with special reference to prolactin, growth hormone and insulin-like growth factor-I.

Authors:  E L Hooghe-Peters; R Hooghe
Journal:  Cell Mol Life Sci       Date:  1998-10       Impact factor: 9.261

Review 5.  Minireview: Extrapituitary prolactin: an update on the distribution, regulation, and functions.

Authors:  Robert J Marano; Nira Ben-Jonathan
Journal:  Mol Endocrinol       Date:  2014-04-02

6.  PAI-1 mediates the antiangiogenic and profibrinolytic effects of 16K prolactin.

Authors:  Khalid Bajou; Stephanie Herkenne; Victor L Thijssen; Salvino D'Amico; Ngoc-Quynh-Nhu Nguyen; Ann Bouché; Sébastien Tabruyn; Mohammed Srahna; Jean-Yves Carabin; Olivier Nivelles; Cécile Paques; Ivo Cornelissen; Michelle Lion; Agnès Noel; Ann Gils; Stefan Vinckier; Paul J Declerck; Arjan W Griffioen; Mieke Dewerchin; Joseph A Martial; Peter Carmeliet; Ingrid Struman
Journal:  Nat Med       Date:  2014-06-15       Impact factor: 53.440

Review 7.  New insights in prolactin: pathological implications.

Authors:  Valérie Bernard; Jacques Young; Philippe Chanson; Nadine Binart
Journal:  Nat Rev Endocrinol       Date:  2015-03-17       Impact factor: 43.330

8.  Activation of mitogen-activated protein kinases by vascular endothelial growth factor and basic fibroblast growth factor in capillary endothelial cells is inhibited by the antiangiogenic factor 16-kDa N-terminal fragment of prolactin.

Authors:  G D'Angelo; I Struman; J Martial; R I Weiner
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-03       Impact factor: 11.205

Review 9.  Role of prolactin and vasoinhibins in the regulation of vascular function in mammary gland.

Authors:  Carmen Clapp; Stéphanie Thebault; Gonzalo Martínez de la Escalera
Journal:  J Mammary Gland Biol Neoplasia       Date:  2008-01-19       Impact factor: 2.673

10.  Novel fusion protein derived from vasostatin 30 and vasoinhibin II-14.1 potently inhibits coronary endothelial cell proliferation.

Authors:  Gabriela Vazquez Rodriguez; Carmen Gonzalez; Antonio De Leon Rodriguez
Journal:  Mol Biotechnol       Date:  2013-07       Impact factor: 2.695

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.